The treatment patterns described above were also assessed in a subgroup of biologic-experienced patients receiving ixekizumab. Biologic-experienced patients were defined as patients who had claims for IL-17i (secukinumab), subcutaneous TNFi (adalimumab, etanercept, golimumab, and certolizumab), and intravenous TNFi (infliximab, golimumab) in the pre-index period.